



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof



Assessing the Impact of a Pharmacy Provided Personalized Vaccination Recommendation on Immunization Rates of Adolescents

Adrianna Herrman, PharmD, Janelle F. Ruisinger, PharmD, Erin E. Moore, PharmD, Brittany L. Melton, PharmD, PhD



PII: S1544-3191(22)00362-4

DOI: <https://doi.org/10.1016/j.japh.2022.10.017>

Reference: JAPH 1706

To appear in: *Journal of the American Pharmacists Association*

Received Date: 22 July 2022

Revised Date: 26 September 2022

Accepted Date: 17 October 2022

Please cite this article as: Herrman A, Ruisinger JF, Moore EE, Melton BL, Assessing the Impact of a Pharmacy Provided Personalized Vaccination Recommendation on Immunization Rates of Adolescents, *Journal of the American Pharmacists Association* (2022), doi: <https://doi.org/10.1016/j.japh.2022.10.017>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the American Pharmacists Association.

**Assessing the Impact of a Pharmacy Provided Personalized Vaccination
Recommendation on Immunization Rates of Adolescents**

Authors:

Adrianna Herrman, PharmD;

PGY1 Community-Based Pharmacy Resident

Balls Food Stores in Overland Park, KS and the University of Kansas School of Pharmacy in
Lawrence, KS

Janelle F. Ruisinger, PharmD;

Clinical Professor, Associate Dean for Academic Affairs, PGY1 Community-Based Residency
Director

The University of Kansas School of Pharmacy in Lawrence, KS

Erin E. Moore, PharmD; Pharmacy Manager

Balls Food Stores in Overland Park, KS

Brittany L. Melton, PharmD, PhD; Associate Professor

The University of Kansas School of Pharmacy, Department of Pharmacy Practice in Lawrence,
KS

Corresponding Author: Adrianna Herrman

7309 NW 85th Terrace, Kansas City, MO 64153

amherrman0509@gmail.com

Author Contributions:

Adrianna Herrman: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft, Visualization.

Janelle F. Ruisinger: Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Erin E. Moore: Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Brittany L. Melton: Formal Analysis, Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Funding Support: This work was supported by the American Pharmacists Association Foundation [Incentive Grant, 2022]. The funding source did not have any role in research conduction or article preparation.

Previous Presentations: Midwest Pharmacy Residency Conference, May 2022. University of Kansas School of Medicine-Wichita 30th Annual Research Forum Virtual Poster Session, April 2022.

Disclosure: The authors declare no relevant conflicts of interest or financial relationships.

Abstract Word Count: 295

Manuscript Word Count: 2467

Number of Tables: 1

Number of Figures: 1

**Assessing the Impact of a Pharmacy Provided Personalized Vaccination
Recommendation on Immunization Rates of Adolescents**

Authors:

Adrianna Herrman, PharmD;

PGY1 Community-Based Pharmacy Resident

Balls Food Stores in Overland Park, KS and the University of Kansas School of Pharmacy in
Lawrence, KS

Janelle F. Ruisinger, PharmD;

Clinical Professor, Associate Dean for Academic Affairs, PGY1 Community-Based Residency
Director

The University of Kansas School of Pharmacy in Lawrence, KS

Erin E. Moore, PharmD; Pharmacy Manager

Balls Food Stores in Overland Park, KS

Brittany L. Melton, PharmD, PhD; Associate Professor

The University of Kansas School of Pharmacy, Department of Pharmacy Practice in Lawrence,
KS

Corresponding Author: Adrianna Herrman

7309 NW 85th Terrace, Kansas City, MO 64153

amherrman0509@gmail.com

Author Contributions:

Adrianna Herrman: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft, Visualization.

Janelle F. Ruisinger: Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Erin E. Moore: Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Brittany L. Melton: Formal Analysis, Funding Acquisition, Methodology, Writing – Review & Editing, Visualization.

Funding Support: This work was supported by the American Pharmacists Association Foundation [Incentive Grant, 2022]. The funding source did not have any role in research conduction or article preparation.

Previous Presentations: Midwest Pharmacy Residency Conference, May 2022. University of Kansas School of Medicine-Wichita 30th Annual Research Forum Virtual Poster Session, April 2022.

Disclosure: The authors declare no relevant conflicts of interest or financial relationships.

Abstract Word Count: 295

Manuscript Word Count: 2467

Number of Tables: 1

Number of Figures: 1

1 **Assessing the Impact of a Pharmacy Provided Personalized Vaccination**

2 **Recommendation on Immunization Rates of Adolescents**

3 **Abstract**

4 **Background:** Adolescents should receive timely doses of recommended vaccinations. The
5 coronavirus disease 2019 (COVID-19) vaccination approval for adolescents presented an
6 opportunity for community pharmacists to address gaps in adolescent immunization schedules.

7 **Objectives:** The objectives of this research were to: (1) identify adolescent immunization gaps,
8 (2) identify number of patients receiving recommended vaccination(s) at the community
9 pharmacy, (3) determine how many vaccinations were administered after the intervention.

10 **Methods:** Three pharmacies conducted the prospective intervention. Adolescents 11-17 years
11 old initiating the Pfizer COVID-19 vaccination series were eligible to receive a personalized
12 vaccination recommendation (PVR) which included up to three other vaccinations. State
13 immunization information systems were assessed after dose one of the COVID-19 vaccine to
14 create the recommendation(s) and reassessed six months after providing the PVR for accepted
15 recommendations. Patient demographics and number of vaccinations administered were
16 assessed using descriptive statistics.

17 **Results:** Of 225 adolescents who received COVID-19 vaccine dose one, 74.7%, 75.1%, and
18 83.1% were indicated to receive tetanus, diphtheria, and acellular pertussis (Tdap),
19 meningococcal conjugate (MenACWY), or human papillomavirus (HPV) vaccine, respectively.
20 Thirty-three (14.7%) adolescents were up to date on all three vaccinations assessed. Of the 225
21 adolescents, 180 returned to the same location for COVID-19 vaccine dose two and received a
22 PVR. Forty-two caregivers reported their adolescent previously received one or more of the
23 recommended vaccinations indicating that state immunization information systems were
24 inaccurate. Six months after the PVRs were given, 24 vaccinations had been administered.

25 **Conclusion:** A majority of adolescents presenting for a COVID-19 vaccine were indicated,
26 according to state immunization information systems, to receive at least one additional
27 vaccination. Following pharmacist-provided PVR and education, vaccine uptake occurred.
28 Considering caregiver-reported inaccuracies, pharmacists should be cognizant of potential
29 discrepancies when providing PVRs. Additionally, this study highlights the value of a state
30 immunization information system.

31 **Key Words:** Adolescent, Immunization Schedule, COVID-19 Vaccines, Information Systems,
32 Community pharmacy

33 **Key Points:**

34 *What was already known:*

- 35 • COVID-19 pandemic has impacted availability of in-person appointments in which
36 adolescents may receive vaccinations
- 37 • Adolescent vaccination rates in Kansas and Missouri are lower than national averages
38 and suboptimal for age-appropriate vaccinations recommended by the Centers for
39 Disease Control and Prevention
- 40 • Immunization information systems are available resources for healthcare professionals
41 to develop vaccination recommendations

42 *What this study adds:*

- 43 • Adolescent vaccine uptake was observed following a pharmacist-provided personalized
44 vaccination recommendation with accompanying education material
- 45 • Pharmacists in the community setting are poised to promote vaccine uptake and
46 capitalize on vaccination series for adolescents using individualized vaccine
47 recommendations and education material

48 Abbreviations

- 49 Personalized vaccination recommendation (PVR)
50 Centers for Disease Control and Prevention (CDC)
51 Tetanus, diphtheria, and acellular pertussis (Tdap)
52 Meningococcal conjugate (MenACWY)
53 Human papillomavirus (HPV)
54 Coronavirus disease 2019 (COVID-19)

55 Background

56 In Kansas and Missouri, the vaccination rates amongst the adolescent population are
57 suboptimal. As recommended by the Centers for Disease Control and Prevention (CDC),
58 adolescents should receive timely doses of routinely recommended vaccinations.¹ In particular,
59 adolescents are indicated to receive vaccinations that protect against tetanus, diphtheria, and
60 acellular pertussis (Tdap), meningococcal conjugate (MenACWY), and human papillomavirus
61 (HPV).¹

62 Vaccination is important to reduce an adolescent's risk of disease and associated
63 complications.² Tetanus results in about 30 cases annually in the United States, of which nearly
64 all were an individual who did not receive recommended tetanus vaccinations.² Infection with
65 tetanus can result in serious symptoms including inability to open the mouth and difficulty
66 swallowing or breathing with the potential to have significant complications of laryngospasm,
67 fractures, and infections.² Prior to available vaccinations, 100,000-200,000 cases of diphtheria
68 occurred and approximately 14,000 deaths were reported annually.³ Since vaccinations,
69 diphtheria is no longer a leading cause of childhood death in the United States. The rare
70 occurrence of tetanus and diphtheria is encouraging; however, pertussis remains a more
71 frequent occurrence.⁴ Data in the United States from 2013-2017 revealed 7,522 cases of
72 pertussis in the adolescent population, in which hospitalization rate is approximately 0.8%.^{5,6}

73 Despite this, in 2020, the estimated Tdap vaccination coverage in Kansas was 89% and 84% in
74 Missouri which is below the HealthyPeople2020 goal and national coverage estimate of 90%.^{5,7}

75 In 2019, 375 cases of meningococcal disease were reported in the United States.
76 Fortunately this number is relatively low since even with treatment, meningococcal disease is
77 fatal for 10-15% of individuals and up to 20% of survivors will suffer long-term disabilities.⁸
78 Moreover, about one in 20 cases can lead to an outbreak which can negatively impact the
79 affected population.⁸ The MenACWY vaccine can help to protect adolescents from invasive
80 meningococcal disease and any associated long term complications. Estimated vaccination
81 rates against meningococcal disease in 2020 for Kansas was 83% and Missouri was 85% which
82 are both less than the estimated national average of 89%.⁷

83 The vaccination to protect against HPV is a nine valent vaccine. From 2013 to 2016,
84 15% of individuals aged 20 to 34 were positive for one or more HPV types prevented by this
85 available vaccine.⁹ Yet, in 2020, up-to-date HPV vaccination coverage for male and female
86 adolescents aged 13-17 years old in Kansas and Missouri was 53%, below the national average
87 of 59%.⁷ Both states are well below the HealthyPeople2030 goal for 80% of adolescents to be
88 vaccinated against HPV.¹⁰ HPV can lead to anal, cervical, oropharyngeal, penile, vaginal and
89 vulvar cancer. Annually, there are an estimated 34,800 cancer cases resulting from HPV;
90 increasing HPV vaccination rates can be impactful considering 92% of these cancer cases are
91 preventable by vaccination.¹¹

92 The reduction of in-person doctor office visits during the coronavirus disease 2019
93 (COVID-19) pandemic due to infection or risk of exposure was likely a contributing factor to the
94 reduction in adolescents receiving age-appropriate vaccinations.^{12,13} Data assessing
95 vaccinations in the adolescent age group indicated a drastic decline in vaccinations in 2020, by
96 as much as 84% when compared to 2018-2019.¹⁴ Improving these vaccination rates can help to
97 protect the adolescent population from contracting tetanus, diphtheria, pertussis, meningococcal
98 disease, and human papillomavirus. Community pharmacists are accessible healthcare

99 professionals that can serve as vaccinating providers for this population. The 2021-22 influenza
100 season highlighted the scope of pharmacists as vaccinators with 40.4 million individuals
101 receiving an influenza vaccine at a pharmacy compared to 30.8 million at a physician's office.¹⁵
102 Pharmacists are well equipped to provide vaccination services to the adolescent population in
103 the community setting, in turn supporting pediatricians and other vaccinating providers.

104 A state immunization information system allows healthcare providers, including
105 pharmacists, to access an individual's vaccination records. These state registries are designed
106 to be a useful resource to increase transparency of administered vaccinations across different
107 healthcare settings within the state to promote vaccination efforts. Documentation within a state
108 immunization information system can prevent duplicate vaccination recommendations and can
109 aid in timely administered vaccines. Community pharmacist review of state immunization
110 information systems to produce vaccination recommendations can support other healthcare
111 providers.

112 The COVID-19 vaccination authorization for adolescents aged 11-17 years old has
113 presented a unique opportunity for community pharmacists to evaluate and address identified
114 gaps in adolescents' vaccination schedules. This study sought to determine if a pharmacist-
115 provided personalized vaccination recommendation (PVR) for Tdap, MenACWY, and HPV
116 would result in increased vaccine uptake for the adolescent population as determined by
117 immunization registry reporting.

118 **Objectives**

119 The primary objective of this research was to identify immunization gaps for adolescents
120 receiving the COVID-19 vaccination based on immunization registry data. Following the
121 pharmacist-provided PVR, other objectives were to identify the number of patients who received
122 vaccination(s) in the community pharmacy setting and to determine how many vaccinations
123 were administered to adolescents after the intervention altogether.

124 **Methods**

125 *Study Site*

126 A prospective intervention was conducted at three pharmacy sites operated by a grocery
127 store chain located in the Kansas City metropolitan area. All three sites were Kansas
128 pharmacies located within 25 miles of the Missouri border, so residents of both states comprise
129 the patient populations at each site.

130 *Inclusion and Exclusion Criteria*

131 Adolescents 11 to 17 years old initiating the Pfizer COVID-19 vaccination series at any
132 of the three study sites were eligible for a PVR. Anyone who received dose one of the COVID-
133 19 vaccine prior to the start of the study did not allow for sufficient time for development of the
134 PVR and was excluded. Additionally, anyone who did not return to the same site for their
135 second COVID-19 vaccine dose was excluded from analysis.

136 *Study Approach*

137 Adolescents initiating the COVID-19 vaccine series between October 2021 and
138 December 2021 were eligible to receive a PVR. Insurance information and the COVID-19
139 vaccination consent form containing the patient's name and date of birth were collected at
140 COVID-19 vaccine dose one administration. Between dose one and dose two of the COVID-19
141 vaccine series, the information from the consent form was used to search the Kansas
142 immunization information system "WebIZ" and Missouri immunization information system
143 "ShowMeVax" to obtain immunization records. After assessing the state immunization
144 information systems, a PVR for each adolescent was developed which included the vaccine(s)
145 that were due to be administered based on CDC recommendations. For each recommended
146 immunization, the associated copayments for pharmacy administration and a patient friendly
147 vaccine education handout from the CDC were included. The PVR and vaccine education
148 handout(s) were attached to the patient's consent form used for both doses of the COVID-19
149 vaccine series. When the adolescent returned to the pharmacy for dose two of the COVID-19
150 vaccine, the community pharmacist or pharmacy intern retrieved the consent form, provided the

151 PVR, and gave the education handouts to the caregiver. When providing the PVR, the
152 pharmacist presented the anticipated copayment(s) for vaccine administration of typically zero
153 dollars to the caregiver and offered to administer the adolescent's recommended vaccination(s)
154 at this time. If the caregiver declined the offered vaccination(s), the PVR handout instructed
155 caregivers on how to schedule an appointment to receive the recommended vaccination(s) at
156 the pharmacy and walk-in availability. Six months after the PVR was provided to the
157 adolescent's caregiver at COVID-19 vaccine dose two, the immunization information systems
158 were reviewed a second time to determine if the recommended vaccinations were administered.

159 Patient demographics, number of vaccination recommendations, and number of
160 vaccinations administered were assessed using descriptive statistics. Data were evaluated
161 using SPSS v.27. University of Kansas Medical Center Human Subjects Committee granted
162 exemption for this project.

163 **Results**

164 A total of 225 adolescents were eligible for a PVR. The majority of adolescents were
165 white, non-Hispanic, and 11 years old as seen in Table 1. Of the 225 adolescents, 168 (74.7%)
166 were indicated to receive a Tdap vaccination, 169 (75.1%) were indicated to receive a
167 MenACWY vaccination, and 187 (83.1%) were indicated to receive an HPV vaccination as seen
168 in Figure A. Most adolescents 162 (72%) were indicated to receive three vaccinations, while
169 four (1.8%) were indicated for two vaccinations, and 26 (11.5%) were indicated for only one
170 vaccination. Thirty-three (14.7%) adolescents were up to date on all three vaccines.

171 Of the 225 adolescents, 180 (80%) returned to the same site to receive COVID-19
172 vaccine dose two and received their PVR and were therefore included in the analysis. When the
173 PVR was given to the caregiver, 42 (23%) caregivers reported their adolescent previously
174 received one or more of the recommended vaccinations.

175 Within six months after the 180 PVRs were provided to the caregivers, 13 (7.2%) unique
176 patients received 24 vaccinations: six Tdap, six MenACWY, and 12 HPV vaccines. All

177 vaccinations were administered at a pediatrician's office according to the state immunization
178 information systems.

179 **Discussion**

180 To our knowledge, this is the first study to examine pharmacists providing PVRs in
181 coordination with the COVID-19 vaccination series. This study aimed to address any gaps in an
182 adolescent's recommended immunization schedule after assessing Tdap, MenACWY, and HPV
183 immunization status using WebIZ and ShowMeVax. Twenty-four vaccinations were documented
184 six months post intervention indicating that barriers to adolescent vaccinations beyond
185 awareness of needed vaccinations may exist.

186 Olusanya and colleagues assessed barriers to childhood and adolescent vaccination
187 uptake in the United States in the context of the COVID-19 pandemic. Challenges identified
188 which may have contributed to vaccine delay included parental education level, overwhelmed
189 healthcare systems, and restrictions on in-person office appointments resulting in fewer
190 opportunities for providers to encourage vaccinations. The authors recommended healthcare
191 professionals work to increase personalized patient-provider interactions.¹² They also concluded
192 patients should be receiving vaccinations at alternative immunization locations, such as
193 community pharmacies to alleviate bottlenecks elsewhere in the healthcare system.¹²

194 The current study sought to overcome these obstacles, by leveraging contact with a
195 healthcare professional in the community pharmacy to promote vaccine uptake by means of a
196 PVR with education materials provided directly to caregivers. Other attempts made to increase
197 childhood and adolescent vaccination rates have been assessed, primarily involving other
198 healthcare educators including physicians, physician assistants, nurses, nurse practitioners, and
199 medical assistants.¹⁶ Our study focused on pharmacists, expanding existing knowledge of
200 interventions to increase adolescent vaccination rates. Fourteen studies providing health
201 education were reviewed by Oyo-lta and colleagues, six of which focused on interventions
202 either in the community directly or in a healthcare clinic. In the healthcare facility interventions,

203 parents were given verbal vaccine education and provided a PVR at time of clinic visit.¹⁷ These
204 studies concluded that this intervention may have improved the uptake of three doses of
205 diphtheria-tetanus-pertussis vaccine for children.¹⁷ Similarly, providing education and a PVR
206 directly to the caregiver the day of another service and subsequent uptake of vaccines was
207 seen in our study in the community pharmacy setting. While the patients in the Oyo-Ita studies
208 were children, our study involved an adolescent population, indicating that providing education
209 and a PVR to caregivers may improve vaccine uptake regardless of the child's age.¹⁷ Another
210 study focused on presenting HPV health education, including vaccine recommendations and an
211 educational handout, to caregivers of nine to 12 year old females. This caregiver-directed health
212 education intervention resulted in 11 (50%) unvaccinated females initiating the HPV vaccination
213 series during the follow up period.¹⁸ Our results align with this research as our study provided a
214 PVR and educational handouts to each caregiver whose adolescent was indicated for the HPV
215 vaccine; 12 HPV vaccinations were administered within six months of intervention.

216 After receiving the PVR, 42 caregivers reported one or more of the recommended
217 vaccinations had been administered previously. This discrepancy indicates there may be a lack
218 of reporting which is causing statewide immunization information systems to be inaccurate. In
219 Kansas and Missouri, pharmacies are required to report all administered vaccinations to the
220 state immunization information system.¹⁹⁻²¹ Yet, other vaccination providers such as
221 pediatrician's offices, health clinics, and health departments are not mandated to report
222 administered vaccinations to these immunization information systems.¹⁹⁻²¹ Only 58% of US
223 states and territories require all vaccine providers to report to an immunization information
224 system and less than half (39%) require reporting for all ages.²² The optional reporting for some
225 providers in Kansas and Missouri may have led to the immunization information systems not
226 being up to date. With some providers reporting to the state immunization information systems
227 voluntarily, the number of vaccinations needed in the PVR provided to the caregiver could have
228 been falsely elevated due to the lack of required reporting.

229 During the six month follow up period, 24 vaccinations were administered, all of which
230 were administered at a pediatrician's office. The low number of adolescents up to date on
231 vaccinations may have also been due to an increase in telehealth visits due to the risk of
232 exposure of COVID-19 during the peak of the pandemic. As doctor offices started to transition
233 back to in-person appointments, the availability of an appointment may have been an additional
234 factor.

235 On the other hand, after the pharmacist-provided PVR, the true number of vaccinations
236 administered within the six month follow up period could have been higher than results show. If
237 an adolescent received one of the pharmacist-recommended vaccinations from a provider who
238 does not report to the state immunization information system, the data would not have been
239 captured when reassessing the databases at the six month follow up time period. The study
240 highlights the need for all immunization providers to upload records to the respective state
241 immunization information system. This shift would improve the completeness of the
242 immunization information systems; therefore, improving the accuracy of pharmacist-provided
243 PVRs to the adolescent population.

244 *Limitations*

245 This study lacked diversity amongst the study population despite having three different
246 study site locations. Further, lack of voluntary reporting to state immunization information
247 systems may have impacted the completeness of the PVR and the accuracy of number of
248 accepted recommendations.

249 **Conclusions**

250 Pharmacist-provided PVRs impacted vaccination rates amongst the adolescent
251 population. Implementing PVRs allowed community pharmacists to deliver vaccination
252 recommendations individualized for each adolescent directly to their caregivers. Additional
253 studies surrounding increasing adolescent vaccination uptake in the community pharmacy
254 setting and evaluation of state immunization registry regulations would be beneficial.


References

1. Centers for Disease Control and Prevention. Birth-18 years immunization schedule. Centers For Disease Control And Prevention. Published 2021. Accessed August 2021. <https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html>
2. Tetanus. Centers for Disease Control and Prevention. Published 2019. Accessed May 2022. <https://www.cdc.gov/tetanus/about/symptoms-complications.html>
3. Pinkbook: Diphtheria. Centers for Disease Control and Prevention. Published 2021. Accessed May 2022. <https://www.cdc.gov/vaccines/pubs/pinkbook/dip.html>
4. Diphtheria. Centers for Disease Control and Prevention. Published 2020. Accessed May 2022. <https://www.cdc.gov/diphtheria/about/index.html>.
5. Office of Disease Prevention and Health Promotion. Immunization and Infectious Diseases | Healthy People 2020. Healthypeople.gov. Published 2014. Accessed January 2022. <https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases>
6. Pertussis (Whooping Cough). Centers for Disease Control and Prevention. Published 2019. Accessed May 2022. <https://www.cdc.gov/pertussis/clinical/complications.html>.
7. Data Dashboard. Immunize Kansas Coalition. Accessed March 2022. <https://www.immunizekansascoalition.org/datadash.asp>.
8. Meningococcal Disease. Centers for Disease Control and Prevention. Published 2022 February 7. Accessed May 2022. <https://www.cdc.gov/meningococcal/about/diagnosis-treatment.html>.
9. Reduce infections of HPV types prevented by the vaccine in young adults - IID-07 - Healthy People 2030. Accessed January 2022. <https://health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-infections-hpv-types-prevented-vaccine-young-adults-iid-07>
10. Office of Disease Prevention and Health Promotion. Vaccination - Healthy People 2030. Accessed January 2022. <https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination>.
11. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018. *MMWR Morb Mortal Wkly Rep.* 2019;68(33):718-723. Published 2019 Aug 23. Accessed August 2021. doi:10.15585/mmwr.mm6833a2
12. Olusanya OA, Bednarczyk RA, Davis RL, Shaban-Nejad A. Addressing Parental Vaccine Hesitancy and Other Barriers to Childhood/Adolescent Vaccination Uptake During the Coronavirus (COVID-19) Pandemic. *Front Immunol.* 2021;12:663074. Published 2021 Mar 18. Accessed March 2022. doi:10.3389/fimmu.2021.663074
13. Brown CL, Montez K, Amati JB, et al. Impact of COVID-19 on Pediatric Primary Care Visits at Four Academic Institutions in the Carolinas. *Int J Environ Res Public Health.* 2021;18(11):5734. Published 2021 May 27. Accessed May 2022. doi:10.3390/ijerph18115734
14. Kujawski SA, Yao L, Wang HE, Carias C, Chen YT. Impact of the COVID-19 pandemic on pediatric and adolescent vaccinations and well child visits in the United States: A database analysis. *Vaccine.* 2022;40(5):706-713. Published 2022 Jan 31. Accessed September 2022. doi:10.1016/j.vaccine.2021.12.064

15. Influenza vaccinations administered in pharmacies and physician medical offices, adults, United States. Centers for Disease Control and Prevention. <https://www.cdc.gov/flu/fluview/dashboard/vaccination-administered.html>. Published 2022 April 22. Accessed September 2022.
16. Abdullahi LH, Kagina BM, Ndze VN, Hussey GD, Wiysonge CS. Improving vaccination uptake among adolescents. *Cochrane Database Syst Rev*. 2020;1(1):CD011895. Published 2020 Jan 17. Accessed April 2022. doi:10.1002/14651858.CD011895.pub2
17. Oyo-lta A, Wiysonge CS, Oringanje C, Nwachukwu CE, Oduwole O, Meremikwu MM. Interventions for improving coverage of childhood immunisation in low- and middle-income countries. *Cochrane Database Syst Rev*. 2016;7(7):CD008145. Published 2016 Jul 10. Accessed May 2022. doi:10.1002/14651858.CD008145.pub3
18. Winer RL, Gonzales AA, Noonan CJ, Buchwald DS. A Cluster-Randomized Trial to Evaluate a Mother-Daughter Dyadic Educational Intervention for Increasing HPV Vaccination Coverage in American Indian Girls. *J Community Health*. 2016;41(2):274-281. Accessed June 2022. doi:10.1007/s10900-015-0093-2
19. What is ShowMeVax? ShowMeVax | Immunizations | Health & Senior Services. <https://health.mo.gov/living/wellness/immunizations/showmevax/>. Accessed April 2022.
20. 65-1635a. Administration of vaccine; education and reporting requirements; exceptions; delegation of authority prohibited; "pharmacist" defined. Kansas Office of Revisor of Statutes. https://www.ksrevisor.org/statutes/chapters/ch65/065_016_0035a.html. Accessed April 2022.
21. Kansas WebIZ. Immunize Kansas Coalition. https://www.immunizekansascoalition.org/documents/conference_materials/Aug19meeting/KSWebIZ%20Presentation.pdf. Accessed April 2022.
22. Scharf LG, Coyle R, Adeniyi K, et al. Current Challenges and Future Possibilities for Immunization Information Systems. *Acad Pediatr*. 2021;21(4S):S57-S64. Accessed June 2022. doi:10.1016/j.acap.2020.11.008

Table 1: Adolescent Demographics

Table 1: Adolescent Demographics	
Age (Years)	n= 225 (%)
11	167 (74.2%)
12	20 (8.9%)
13	9 (4%)
14	7 (3.1%)
15	6 (2.7%)
16	11 (4.9%)
17	5 (2.2%)
Race	n= 225 (%)
White	140 (62.2%)
Black or African American	9 (4%)
Asian	4 (1.8%)
More than one race	20 (8.9%)
Other	11 (4.9%)
Not listed	41 (18.2%)
Ethnicity	n= 225 (%)
Hispanic	12 (5.3%)
Not Hispanic	144 (64%)
Not listed	69 (30.7%)

Figure A: Percentage of Adolescents Indicated to Receive the Following Vaccines (n=225)

Tdap: Tetanus, diphtheria, and acellular pertussis; MenACWY: Meningococcal conjugate; HPV: Human papillomavirus